Today, AliveDx announces the publication of its ESG Report 2025, marking another year of significant advancement across sustainability, social responsibility, and workplace excellence.
The 2025 report underscores the company’s ongoing commitment to reducing its environmental footprint, advancing social responsibility, and fostering a great place to work.
Key highlights include:
- The headquarters and R&D / manufacturing site in Eysins, Switzerland has been re-certified to ISO 14001. In addition, the UK site successfully completed the ISO 14001 surveillance audit, with no major findings.
- The company has attained Level 2 of the UK NHS Evergreen Assessment by both AliveDx Suisse SA (Switzerland) and Alba Bioscience Ltd. (Scotland, UK).
- Great Place to Work® certification was achieved across all three eligible AliveDx sites (the UK, the US and Switzerland).
AliveDx attributes a significant portion of its 2025 ESG achievements to close collaboration with partners who share the company’s ambition for positive impact. This includes suppliers and contract manufacturers adhering to AliveDx’s Sustainable Procurement Policy, as well as healthcare and distribution partners enabling broader access to advanced diagnostics.
Looking ahead, AliveDx plans to expand energy‑efficiency measures, reduce waste across operations, and pursue innovative approaches to lower emissions throughout the supply chain.
The ESG Report 2025 serves as both a progress update and a roadmap for continued action in line with AliveDx’s mission to empower diagnostic insights and transform patient care.
Please see the full ESG Report 2025 here: AliveDx ESG Report 2025
